Last updated: February 17, 2026
What is NDC 00406-8510?
NDC 00406-8510 corresponds to Jardiance (empagliflozin), a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus. It is marketed by Boehringer Ingelheim and Eli Lilly.
Market Size and Growth Trends
Global Diabetes Market
The global diabetes therapeutics market was valued at approximately $86 billion in 2022. It is projected to increase at a compound annual growth rate (CAGR) of 7.4% through 2028, driven by escalating diabetes prevalence, rising awareness, and expanding treatment options.
Empagliflozin Market Share
Jardiance holds a significant share of the SGLT2 inhibitor segment, which accounted for about 32% of the total diabetes drug sales in 2022. The segment grew 10% year-over-year, reflecting strong adoption.
Key Competitors
- Dapagliflozin (Farxiga) (AstraZeneca): Leader, with $2.6 billion sales in 2022.
- Canagliflozin (Invokana) (Janssen): Approximate $953 million sales in 2022.
- Other entrants include ertugliflozin (Steglatro) and sotagliflozin (Zynquista).
Market Drivers
- Cardiovascular and renal benefits demonstrated in CVOTs (cardiovascular outcomes trials).
- Broader label expansions, including indications for heart failure and chronic kidney disease (CKD).
- Increasing adoption in multiple regions, especially in North America and Europe.
Price Analysis and Projections
Current Pricing Structure
Wholesale acquisition cost (WAC) for a 30-day supply of Jardiance (empagliflozin 10 mg) is approximately $600–$700. Pricing varies by pharmacy benefit managers (PBMs), region, and insurance coverage.
Pricing Trends
- Prices for SGLT2 inhibitors have remained relatively stable over the past three years.
- Entry of biosimilars is unlikely, as Jardiance is a small-molecule branded drug, but competition from generics is not expected until patents expire.
Patent Status and Patent Expiry
- Primary patents extend into 2030, with additional formulation and method-of-use patents until 2035[1].
- Patent expiry influences generic entry and price erosion.
Future Price Projections
- No significant price reductions are forecasted before 2025 barring market disruptions.
- Post-patent expiration (estimated 2030–2035), generic versions could reduce prices by 60–80%.
- Continued adoption of Jardiance in expanding indications may sustain or slightly increase its current price point.
Regulatory and Policy Impact
Reimbursement Trends
- PBMs tend to favor drugs with proven cardiovascular and renal benefit data, which supports Jardiance's premium price.
- Value-based reimbursement models may incentivize price stabilization or modest reductions.
Market Access
- Expanded approvals in heart failure and CKD broaden the patient population, supporting sales longevity.
- Price sensitively impacted by formulary placement and patient co-insurance.
Investment and R&D Outlook
Pipeline Drugs
- Boehringer Ingelheim and Lilly are developing next-generation SGLT2 inhibitors and combination therapies.
- Entry of superior formulations or combination products could impact Jardiance’s market share and pricing.
R&D Spending
- Lilly estimates R&D expenses for diabetes therapies to be approximately $1.2 billion annually, emphasizing continued pipeline investment.
Summary Table
| Aspect |
Data |
| Current Market Size |
$86 billion (global diabetes market, 2022) |
| Empagliflozin Segment |
32% of SGLT2 inhibitor segment sales, >$2 billion globally (2022) |
| Key Competitors |
Dapagliflozin (Farxiga), Canagliflozin (Invokana) |
| WAC (30-day supply) |
$600–$700 |
| Patent Expiry |
~2030–2035 |
| Price Reduction Post-Patent |
Up to 80% reduction anticipated after patent expiry |
Key Takeaways
- Jardiance maintains a dominant position within the SGLT2 inhibitor class due to demonstrated cardiovascular and renal benefits.
- Market growth remains strong, bolstered by expanded indications and improved clinical data.
- Current prices are stable but are expected to decline significantly after patent expiration, likely around 2030–2035.
- Price projections are cautious, with no immediate downward pressure until patent expiry and generic entry occur.
- Market access policies favor drugs with proven outcomes, reinforcing Jardiance’s premium pricing.
FAQs
1. When will Jardiance face generic competition?
Patent rights extend into the early 2030s, with potential generic or biosimilar entry after 2030.
2. How does Jardiance compare to other SGLT2 inhibitors in pricing?
Prices are comparable; Pfizer’s Farxiga and Janssen’s Invokana have similar WACs, with slight variations based on formulary decisions.
3. What factors influence Jardiance’s pricing stability?
Clinical benefit data, regulatory approvals, and payer reimbursement policies predominantly affect pricing.
4. Could biosimilar competition impact Jardiance’s market share?
Not directly, as Jardiance is a small molecule. However, competition from generics post-2030 may pressure prices.
5. What is the outlook for Jardiance in non-diabetes indications?
Registrations for heart failure and CKD indications are expanding the market, potentially increasing revenue streams.
References
[1] U.S. Patent and Trademark Office databases.
